摘要
为了探讨人精子蛋白17(Sp17)放免分析的临床意义,用自建的Sp17放免分析方法,测定了正常人及部分癌症患者血清Sp17值。结果显示,卵巢癌、子宫内膜癌患者血清Sp17值分别为36.02±27.95μg/L,40.29±21.15μg/L,与对照组15.60±7.66μg/L相比,有显著性差异(P<0.01);而且部分卵巢癌、子宫内膜癌患者血清Sp17值明显升高。因此血清Sp17浓度的测定可能有助于卵巢癌、子宫内膜癌症等患者的诊断和治疗,值得进一步研究。
To evaluate value of RIA for human sperm protein 17 （Sp17）, Sp17 levels were measured by radioimmunoassay in normal subjects and in some patients with carcinoma. There were significant differences in serums Sp17 levels between normal subjects （ 15. 60 ±7.66μg/L） and patients with ovarian carcinoma （36.02±27.95μg/L） and endometrial cancer（40. 29± 21.15μg/L） （P〈0. 01 ）o Serums Sp17 levels in patients with ovarian carcinoma and endometrial cancer were significantly elevated. Therefore, measurement of Sp17 was possibly useful for clinical diagnosis and choice of treatment of some patients with ovarian carcinoma and endometrial cancer.
出处
《标记免疫分析与临床》
CAS
2006年第3期141-142,共2页
Labeled Immunoassays and Clinical Medicine
